These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9096181)

  • 21. Pore-forming pyocin S5 utilizes the FptA ferripyochelin receptor to kill Pseudomonas aeruginosa.
    Elfarash A; Dingemans J; Ye L; Hassan AA; Craggs M; Reimmann C; Thomas MS; Cornelis P
    Microbiology (Reading); 2014 Feb; 160(Pt 2):261-269. PubMed ID: 24217175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins].
    Croize J; Le Noc P; Bryskier A; Robert J
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):564-8. PubMed ID: 3937128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ciprofloxacin induction of a susceptibility determinant in Pseudomonas aeruginosa.
    Brazas MD; Hancock RE
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3222-7. PubMed ID: 16048929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pyocin-sensitivity testing as a method of typing Pseudomonas aeruginosa: use of "phage-free" preparations of pyocin.
    Rampling A; Whitby JL; Wildy P
    J Med Microbiol; 1975 Nov; 8(4):531-41. PubMed ID: 812999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Postantibiotic effects and postantibiotic effects of subinhibitory levels of quinolines on Pseudomonas aeruginosa].
    Hostacká A
    Epidemiol Mikrobiol Imunol; 1996 May; 45(2):56-8. PubMed ID: 8756401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparative activities in vitro of 4 quinolones (nalidixic acid, pefloxacin, norfloxacin, ofloxacin) on 13 bacterial species].
    Rahal K
    Arch Inst Pasteur Alger; 1992; 58():41-84. PubMed ID: 1309146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [In vitro activity of seven gyrase inhibitors of a group of heterocyclic carbonic acids against nonfermenting gram negative rods (nonfermenters)].
    Grimm H
    Arzneimittelforschung; 1985; 35(3):570-2. PubMed ID: 2986655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Susceptibility pattern of bacterial isolates to lomefloxacin.
    Lalitha MK; Nisha AK; Bhattacharya SS; Ramamoorthy U; Lal HM
    Indian J Med Res; 1990 May; 91():182-4. PubMed ID: 2397938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Purification and properties of an S-type pyocin, pyocin AP41.
    Sano Y; Kageyama M
    J Bacteriol; 1981 May; 146(2):733-9. PubMed ID: 6783626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro emergence of Escherichia coli and Pseudomonas aeruginosa strains resistant to norfloxacin and nalidixic acid.
    Piffaretti JC; Demarta A; Leidi-Bulla L; Peduzzi R
    Eur J Clin Microbiol; 1983 Dec; 2(6):600-1. PubMed ID: 6230227
    [No Abstract]   [Full Text] [Related]  

  • 32. Antimicrobial resistance in clinical isolates of Salmonella enterica serotype Enteritidis: relationships between mutations conferring quinolone resistance, integrons, plasmids and genetic types.
    Soto SM; González-Hevia MA; Mendoza MC
    J Antimicrob Chemother; 2003 May; 51(5):1287-91. PubMed ID: 12668577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence on Pseudomonas aeruginosa elastase, proteinase and alginate by supra-inhibitory and supra-subinhibitory concentrations of quinolones.
    Hostacká A; Majtán V
    Microbios; 1996; 87(352):141-7. PubMed ID: 9050251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid measurement of bacterial sensitivity to ampicillin and nalidixic acid.
    Chadwick P
    Can Med Assoc J; 1967 Sep; 97(14):846-51. PubMed ID: 4963759
    [No Abstract]   [Full Text] [Related]  

  • 35. A predicted immunity protein confers resistance to pyocin S5 in a sensitive strain of Pseudomonas aeruginosa.
    Rasouliha BH; Ling H; Ho CL; Chang MW
    Chembiochem; 2013 Dec; 14(18):2444-6. PubMed ID: 24222552
    [No Abstract]   [Full Text] [Related]  

  • 36. [Comparison of the in vitro activity of 6 quinolones on Pseudomonas sp].
    Lesage D; Delisle-Mizon F; Vergez P; Daguet GL
    Pathol Biol (Paris); 1985 May; 33(5):412-5. PubMed ID: 3162141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.
    Aubert G; Pozzetto B; Dorche G
    J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R; Michéa-Hamzehpour M; Pechère JC
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance of Vibrio cholerae 01 to nalidixic acid.
    Jesudason MV; Saaya R
    Indian J Med Res; 1997 Apr; 105():153-4. PubMed ID: 9145595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In-vitro activity of fleroxacin compared with three other quinolones.
    Bremner DA; Dickie AS; Singh KP
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():19-23. PubMed ID: 3144536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.